|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||76.73 - 77.70|
|52 Week Range||39.30 - 77.70|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||76.94|
|Earnings Date||Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||508.91|
The increasing diversity of SARS-CoV-2 variants and the potential higher infectivity of some new viral strains, underline the need to identify, trace and track mutations across the complete viral genome. Currently, strains of concern include the B.1.1.7 variant, first identified in the United Kingdom, and the B.1.351 variant, first identified in South Africa.
Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus.
Eurofins GeneScan Technologies (Paris:ERF) announces that the VIRSeek SARS-CoV-2 Solution has been evaluated and approved by the AOAC Performance Tested MethodsSM (PTM) Program on December 29, 2020 and awarded Emergency Response Validation PTM certification number 122006. The VIRSeek SARS-CoV-2 Solution is a comprehensive workflow for the detection of SARS-CoV-2 on environmental surfaces that includes swabbing of environmental surfaces, RNA extraction, analysis by Reverse Transcription PCR (RT-PCR) and evaluation by an advanced algorithm.